As demonstrated in past research studies, the development of neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), begins as early as 10 to 20 years before clinical manifestation. Because of this and the degenerative nature of these diseases, early diagnosis is crucial in patients’ abilities to gain access to treatments and the opportunity to participate in clinical trials of novel therapies.
Stem cell therapy for neurodegenerative disease is among many emerging and experimental methods aimed at disease modification. The increased research and interest in stem cell therapy shed light on a newer methodology that focuses on shifting from a reactive to restorative or regenerative approach in medicine, meaning rather than treating the symptoms of a disease after they arise, this approach focuses on repairing the damage itself.
Below, we take a closer look into stem cell therapy for neurodegenerative diseases, including a comparison of stem cell types, an overview of existing research, and the need for robust measurement tools to identify minute changes in neurocognitive function to enable early detection of neurodegenerative diseases.
Put simply, stem cells are unique cells that can self-renew and differentiate into any cell type in the body, including neurons. They are essentially the body’s master cells—cells from which all other cells with specialized functions are generated. Below is a comparison of the various types of stem cells:
|Type of Stem Cell||Source||Advantages||Disadvantages|
|Embryonic stem cells (ESCs)(pluripotent)||Embryo (blastocyst)||
|Induced pluripotent stem cells (iPSCs) (pluripotent)||Reprogrammed adult cells: hepatocytes, fibroblasts, circulating T cells, and keratinocytes||
|Mesenchymal stem cells (MSCs) (multipotent)||Adult tissues (e.g. skin, blood, bone marrow, umbilical cord, etc.)||
||Risk of tumor development|
|Neural stem cells (NSCs)||Embryo, human fetal brain, brain tissue of adults||Low risk of tumor development||
While still controversial and in need of further research, particularly in humans, stem cell therapy is one of the only potential treatment modalities that offer a means to not only prevent further damage but potentially repair and heal damage.
These innovative treatment strategies are due to the capability of stem cells to repair injured neuronal tissue by replacing damaged cells with differentiated cells. This creates an optimal and conducive environment for potential regeneration or protection of existing healthy neurons and glial cells from damage.
Neurodegenerative diseases, including AD, PD, HD, FTD, and ALS, are characterized by a progressive loss of structure, function, or neurons in the brain or spinal cord. Stem cell therapy for neurodegenerative disease typically focuses on either 1) cellular replacement or 2) providing environmental enrichment. Regardless, these approaches involve the regeneration of neural tissue, stabilization of neuronal networks, neurotrophic support, and alleviation of neurodegeneration at various neural circuitry levels.
Dopamine is a key neurotransmitter that transmits signals between neurons and plays a crucial role in movement and motor control. Functional impairments associated with PD are believed to be caused by dopamine deficits in the striatum resulting from the destruction of dopamine-producing neurons located in the substantia nigra.
Over the past 20 years, researchers have investigated potential strategies to utilize stem cells to supplement dopamine by replacing the lost dopaminergic neurons with stem cell-derived equivalents. Currently, researchers are working to utilize ESCs, iPSCs, and NSCs to induce the differentiation of such stem cells into mature dopaminergic cells.
Stem cell therapy for the treatment of PD has proven successful in many animal studies, including in monkey, pig, rat, and mice models. The first clinical trials investigating the use of stem cell therapy aiming to combat the loss of substantia nigra neurons are already underway in the U.S., Japan, and Europe.
It should be noted that stem cell therapy is not a cure for PD, or any disease for that matter, and there is a potential for this treatment to result in side effects more challenging to control than PD itself. However, the continuation of research in this space could one day yield promising approaches for restorative therapies.
Experts estimate that impairments in a person’s movement due to PD are noticeably affected once roughly 50-80% of neurons are lost, meaning substantial damage is already done. This further emphasizes the urgent need for robust measurement tools to identify minute changes in neurocognitive function to enable early detection of neurodegenerative diseases—PD in particular.
At Altoida, we are dedicated to enabling early detection of neurodegenerative diseases to enable patients to receive the best and more effective care and treatment possible.
We are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.
By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.
Our approach, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. After our Breakthrough Device designation by the FDA, Altoida’s device will provide patients with a predictive score that will enable a highly accurate prediction of whether a patient aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease.
To learn more about stem cell therapy for neurodegenerative disease or about how Altoida’s Precision Neurology platform and medical device will enable early detection, contact us today.